Coverage of "LLY stock" on cryptobo.eu: the stories and the context behind them.
Eli Lilly pushed its retatrutide FDA filing to early 2027, citing manufacturing data requirements, even as Phase 3 trials showed patients losing more than 22% of body weight in 80 weeks.
